References
1. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Swerdlow SH, Campo E, Harris NL, et al Eds. IARC Press, Lyon, 2017.
2. Seymour JF, Kipps TJ, Eichhorst B et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378:1107-1120, 2018.3.
3. Cheson BD, Heitner Enschede S, Cerri E et al. Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist 22:1283-1291, 2017.
4. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:2089-2100, 2005.
5. Swan D, Delaney C, Natoni A, O’Dwyer M, Krawczyk J. Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14). Hematologica 105:e141-e143, 2020.
6. Salem AH, Agarwal SK, Dunbar M, Enschede SLH, Humerickhouse RA, Wong SL. Pharmacokinetics of Venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol 57:484-492, 2017.
7. Salem AH, Dave N, Marbury T et al. Pharmacokinetics of the BCL-2 inhibitor Venetoclax in subjects with hepatic impairment. Clin Pharmacokinet 58:1091-1100, 2019.